May 2024 in “Pigment International” Several treatments are effective for pigmentary disorders like vitiligo and melasma.
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
January 2022 in “Medical research archives” Taking vitamin D might improve life for MS patients and reduce skin side effects from alemtuzumab treatment.
[object Object] January 2019 in “Elsevier eBooks” Different hair disorders have specific treatments and outcomes, with some resolving on their own and others requiring medication or emotional support.
July 2018 in “Elsevier eBooks” The most common cause of hair loss in children is tinea capitis, followed by alopecia areata and telogen effluvium.
July 2018 in “Elsevier eBooks” Up to half of people experience itchy scalp, often due to skin conditions like seborrheic dermatitis or psoriasis, and treatments vary based on the specific cause.
80 citations,
April 2018 in “Trends in Molecular Medicine” Lichen Planopilaris and Frontal Fibrosing Alopecia may help us understand hair follicle stem cell disorders and suggest new treatments.
9 citations,
May 2016 in “Clinics in dermatology” Phototherapy can help treat hair loss in alopecia areata.
2 citations,
June 2016 in “Dermatologic Clinics” Dermatologists often neglect hair disorders due to complexity and lack of clear treatments, impacting patient care and highlighting the need for better education and interest in this area.
November 2023 in “Dermatologica sinica/Zhōnghuá pífūkē yīxué zázhì” Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.
June 2017 in “Poster presentations” All four treatments for early rheumatoid arthritis had similar safety profiles.
October 2024 in “Canadian Journal of Health Technologies” Olumiant should be covered for severe alopecia areata if certain conditions are met.
3 citations,
April 2023 in “Dermatologica Sinica” PRP treatment may help with alopecia areata, especially in newer cases.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
5 citations,
October 2014 in “Methods” The document explains how to create detailed biological pathways using genomic data and tools, with examples of hair and breast development.
[object Object] 3 citations,
December 2018 in “Meta Gene” Certain gene variations increase male hair loss risk, influenced by hormone levels.
January 2024 in “Skin appendage disorders” Using growth factors and microneedling shows promise for hair regrowth in Alopecia Areata, but more research is needed.
6 citations,
January 2015 in “Evidence-based Complementary and Alternative Medicine” Saw palmetto extract may help treat brain tumors by blocking a specific growth signal and blood vessel formation.
7 citations,
June 2000 in “Journal of the American Academy of Dermatology” Foam corticosteroid covers as well as traditional forms.
254 citations,
January 2012 in “Nature Reviews Molecular Cell Biology” Stem cell offspring help control their parent stem cells, affecting tissue health, healing, and cancer.
20 citations,
December 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.
8 citations,
June 2022 in “Frontiers in Medicine” Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
3 citations,
March 2020 in “International Journal of Dermatology” Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
December 2024 in “Frontiers in Pediatrics” Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
July 2024 in “Journal of Controlled Release” Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.
January 2024 in “JEADV clinical practice” The study helps doctors use patient images to understand and apply SALT scores for treating severe alopecia areata.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
13 citations,
February 2017 in “Clinical rheumatology” Tofacitinib may help treat nail dystrophy, especially when other treatments fail.
148 citations,
December 2018 in “Journal of autoimmunity” Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.
55 citations,
October 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.